Mr Jim B Gann Jr, RPH in Horton, AL - Pharmacist

Mr Jim B Gann Jr, RPH is a Pharmacist based in Horton, Alabama. Mr Jim B Gann Jr is licensed to practice in Alabama (license number 11616) and his current practice location is 9461 Al Highway 75, Horton, Alabama. He can be reached at his office (for appointments etc.) via phone at (256) 593-1750.

NPI number for Mr Jim B Gann Jr is 1487240230 and his current mailing address is Po Box 28, Douglas, Alabama. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1487240230.

Contact Information

	Mr Jim B Gann Jr, RPH
	9461 Al Highway 75, Horton, AL 35980-8399
	(256) 593-1750
	(256) 593-1711

Healthcare Provider's Profile

Full Name	Mr Jim B Gann Jr
Gender	Male
Speciality	Pharmacist
Location	9461 Al Highway 75, Horton, Alabama
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1487240230
Provider Enumeration Date: 12/16/2020
Last Update Date: 12/16/2020

Medical Identifiers

Medical identifiers for Mr Jim B Gann Jr such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1487240230	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	11616 (Alabama)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mr Jim B Gann Jr is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mr Jim B Gann Jr, RPH Po Box 28, Douglas, AL 35964-0028 Ph: (256) 593-1750	Mr Jim B Gann Jr, RPH 9461 Al Highway 75, Horton, AL 35980-8399 Ph: (256) 593-1750

News Archive

AIDS 2010 to highlight epidemic in Eastern Europe, Central Asia regions

AIDS 2010, the International AIDS Conference to be held July 18-23 in Vienna, Austria, will "highlight the situation in Eastern Europe and Central Asia, regions experiencing fast growing [HIV/AIDS] epidemics largely through unsafe injecting drug use," conference organizers announced Wednesday, Agence France-Presse reports.

Biovail and Alexza Pharmaceuticals sign collaboration and license agreement for anti-agitation drug

Biovail Corporation today announced that its subsidiary, Biovail Laboratories International SRL (BLS), has entered into a collaboration and license agreement with Alexza Pharmaceuticals, Inc.

Cerimon Pharmaceuticals acquires rights to develop and commercialize diclofenac sodium patch in Europe

Cerimon Pharmaceuticals, Inc., announced today that it has acquired exclusive rights to develop and commercialize its once-daily topical diclofenac sodium patch in Europe, including most countries in the European Union, Turkey, Switzerland, Norway, the Balkan countries and Iceland. Terms of the agreement were not disclosed. Cerimon initially acquired the U.S. rights to develop and commercialize the patch formulation of diclofenac in 2005.

FDA Commissioner revokes approval of Genentech's Avastin for treatment of mBC

Genentech, a member of the Roche Group, announced today that the FDA Commissioner is revoking the approval of Avastin (bevacizumab) for the treatment of mBC in the United States.

Mr Jim B Gann Jr, RPH - Pharmacist in Horton, AL